{"id":"NCT01853072","sponsor":"Alcon Research","briefTitle":"Nepafenac Once Daily for Macular Edema - Study 1","officialTitle":"Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06","primaryCompletion":"2015-05","completion":"2015-05","firstPosted":"2013-05-14","resultsPosted":"2016-08-03","lastUpdate":"2016-08-03"},"enrollment":881,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Proliferative Diabetic Retinopathy","Cataract"],"interventions":[{"type":"DRUG","name":"Nepafenac Ophthalmic Suspension, 0.3%","otherNames":["Nepafenac"]},{"type":"OTHER","name":"Nepafenac vehicle","otherNames":[]},{"type":"DRUG","name":"Prednisolone acetate","otherNames":["Omnipred™","Prednisolone acetate ophthalmic suspension"]}],"arms":[{"label":"Nepafenac","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate superiority of Nepafenac Ophthalmic Suspension, 0.3% dosed once daily relative to Nepafenac Vehicle based upon clinical outcomes among diabetic subjects following cataract surgery.","primaryOutcome":{"measure":"Percentage of Participants With Best-corrected Visual Acuity (BCVA) Improvement of ≥ 15 Letters From Preoperative Baseline to Day 14 and Maintained Through Day 90","timeFrame":"Baseline to Day 14, and maintained through Day 90","effectByArm":[{"arm":"Nepafenac","deltaMin":61.7,"sd":null},{"arm":"Vehicle","deltaMin":43,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":881},"commonTop":[]}}